Could a diabetes drug boost heart surgery success?
NCT ID NCT07331727
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This trial tests whether dapagliflozin, a drug typically used for diabetes, can reduce the return of atrial fibrillation after a heart ablation procedure. The study focuses on patients with persistent AF and increased epicardial adipose tissue (heart fat), which is linked to higher recurrence risk. About 280 participants will receive either dapagliflozin or standard care for 3 months after ablation. The main goal is to see if the drug lowers the amount of time spent in atrial arrhythmia.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
dapagliflozin (a diabetes drug that may also reduce heart fat and inflammation)
What this could lead to
If it works, this could offer a new way to improve ablation success in persistent atrial fibrillation patients with excess heart fat.
What could go wrong
This is an early-stage trial with no phase assigned, so results are uncertain. The drug may not reduce recurrence, and side effects like dehydration or urinary infections are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATRIAL FIBRILLATION (AF) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Chest Hospital
Shanghai, China
Contact Email: •••••@•••••